Advancing Accessible Solutions for Complex Neurodegenerative Diseases
Protecting neurons to advance treatment for neurodegenerative diseases
Zervimesine (CT1812) is Cognition Therapeutics’ investigational first-in-class therapy designed to protect brain synapses before irreversible neuronal decline occurs.
As a once-daily, small-molecule oral therapy, zervimesine may offer an accessible solution for people with neurodegenerative diseases, such as dementia with Lewy bodies (DLB) and Alzheimer’s disease.Â
Zervimesine may help protect synaptic integrity and function in age-related neurodegenerative diseases.
Areas of Focus
Alzheimer’s disease is characterized by the age-related buildup of toxic protein oligomers in the brain, which bind to neurons and disrupt normal brain function. Zervimesine (CT1812) has been shown to block toxic oligomers implicated in synaptic damage.
Watch our mechanism of action video to learn more.
Age-related buildup of toxic proteins is also linked to the progression of dementia with Lewy bodies (DLB) – the second most common form of degenerative dementia after Alzheimer’s. Despite the prevalence of DLB, no approved disease-modifying therapies exist, and DLB remains understudied, under-addressed, and largely unrecognized as a public health crisis